Webinar
Join Wilson Sonsini for a Drug Hunter Flash Talk webinar featuring Deborah Smith and Julia Minitti, partners in the Patents and Innovations group, as they explore how antibody-drug conjugates (ADCs) are reshaping the oncology landscape and what that means for intellectual property strategy. Drawing on Drug Hunter’s mission to deliver actionable insights for drug discovery professionals, this session will provide a practical roadmap for building durable IP portfolios in an increasingly crowded ADC space. The discussion will cover best practices for layering patent protection across ADC components, managing freedom-to-operate risk early in R&D, and navigating recent USPTO developments that can directly impact the long-term commercial success of ADC programs.
Melissa Schmidt
melissa.schmidt@wsgr.com
Deborah Smith leads Wilson Sonsini’s Patents and Innovations practice in Southern California. She advises high-growth biotechnology and pharmaceutical companies and their investors on IP strategy across the full product lifecycle—from platform development through drug approval, commercialization, and exit—spanning modalities including small molecules, ADCs, degraders, molecular glues, peptides, nucleic acid therapeutics, biologics, and protein conjugates. Her work spans patent strategy, portfolio development, IP due diligence, and IP matters tied to regulatory approval, as well as transactional matters including buy-side and sell-side M&A, licensing, financings, IPOs, and reverse mergers.
Julia Minitti is a partner in Wilson Sonsini's patent and innovation strategies practice.